Home › Trial NCT01087294
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
- Trial IDNCT01087294
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorNational Cancer Institute (NCI)
- Enrollment85
- Start date2010-08-04
- ConditionsLeukemia, B-cell · Lymphoma, Hodgkins · Lymphoma, Non-hodgkins · Lymphoma, B-Cell
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.